As you know, breast cancer cannot simply be considered as a single disease, or one that can be treated with one generic approach anymore. Instead, it’s becoming clear that the different molecular subtypes of breast cancer may require a different treatment approach in each case. Therefore, the careful identification and separation of different subtypes is the key to a successful – and fully patient-centered - treatment strategy. This is exactly why MammaTyper® exists today.
While IHC has for years been the "go to" solution for breast cancer diagnosis, two things have become apparent.
Standardisation of IHC has just not happened, in any healthcare system you will find multiple stain and antibody options used, add in methodology differences and you could run to hundreds of potential methods for detecting the same analyte.
The limited sensitivity of staining and visual determination has led to many "grey zones" and difficult patient groups. The enhanced sensitivity of PCR and genomics has filtered into many parts of Oncology testing and treatment. Modern treatment options require a modern diagnostic approach.
MammaTyper® was developed by genomic specialists, for just this reason, and it’s the reason we hope you will partner with us to take the next significant step in the diagnosis and treatment of breast cancer.
Different molecular subtypes of Breast Cancer require a different treatment approach in each case.READ MORE +
Today’s science assumes that the development of cancer is a multi-step process of changes or mutations in the genes responsible for regulating the growth of cells.READ MORE +